Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study.

Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, Moodley P, Galvani AP, Friedland GH.

Lancet. 2007 Oct 27;370(9597):1500-7.

2.

The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach.

Basu S, Galvani AP.

Epidemiol Infect. 2008 Dec;136(12):1585-98. doi: 10.1017/S0950268808000964. Epub 2008 Jul 7. Review.

3.

Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.

Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G; Tugela Ferry Care and Research (TF CARES) Collaboration..

J Infect Dis. 2007 Dec 1;196 Suppl 3:S482-90. doi: 10.1086/521121. Review.

PMID:
18181698
4.

The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.

Goldman RC, Plumley KV, Laughon BE.

Infect Disord Drug Targets. 2007 Jun;7(2):73-91. Review.

PMID:
17970220
5.

Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings.

Nardell E, Dharmadhikari A.

Int J Tuberc Lung Dis. 2010 Oct;14(10):1233-43. Review.

6.
7.

Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions.

Prasad R.

Indian J Tuberc. 2010 Oct;57(4):180-91. Review.

PMID:
21141336
8.

Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.

Chang KC, Yew WW.

Respirology. 2013 Jan;18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x. Review.

9.

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.

Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KG, Sirgel FA, Gey van Pittius NC, van Helden PD, Victor TC, Warren RM.

Infect Genet Evol. 2012 Jun;12(4):686-94. doi: 10.1016/j.meegid.2011.07.019. Epub 2011 Aug 4. Review.

PMID:
21839855
10.

Nosocomial multidrug-resistant tuberculosis--global spread of the third epidemic.

Nolan CM.

J Infect Dis. 1997 Sep;176(3):748-51. Review. No abstract available.

PMID:
9291324
11.

Hospital infection control in an era of HIV infection and multi-drug resistant tuberculosis.

Hannan MM, Azadian BS, Gazzard BG, Hawkins DA, Hoffman PN.

J Hosp Infect. 2000 Jan;44(1):5-11. Review.

PMID:
10633047
12.

Transmission of tuberculosis in resource-limited settings.

Kompala T, Shenoi SV, Friedland G.

Curr HIV/AIDS Rep. 2013 Sep;10(3):264-72. doi: 10.1007/s11904-013-0164-x. Review.

13.

[Multidrug resistant tuberculosis: what is the risk in france?].

Bouvet E.

Rev Prat. 2007 Sep 15;57(13):1405-8. Review. French.

PMID:
18018538
14.

Multidrug-resistant and extensively drug-resistant tuberculosis: a review.

Chan ED, Iseman MD.

Curr Opin Infect Dis. 2008 Dec;21(6):587-95. doi: 10.1097/QCO.0b013e328319bce6. Review.

PMID:
18978526
15.

[Emergence extensive drug resistance tuberculosis (XDR)].

Vier H, Schaberg T, Gillissen A.

Pneumologie. 2007 Sep;61(9):606-9. Review. German.

PMID:
17729211
16.

The "new tuberculosis" and its changing epidemiology. Nosocomial transmission and hospital discharge standards.

Blumberg HM.

J Med Assoc Ga. 1995 May;84(5):209-14. Review. No abstract available.

PMID:
7782706
17.

Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?

Kunkel A, Furin J, Cohen T.

Lancet Infect Dis. 2017 May 19. pii: S1473-3099(17)30299-2. doi: 10.1016/S1473-3099(17)30299-2. [Epub ahead of print] Review.

PMID:
28533094

Supplemental Content

Support Center